MITOTHERAPEUTIX
Mitotherapeutix develops siRNA-based drugs that focus on addressing difficult disease targets. Mitotherapeutix targets and controls the metabolic activity in the mitochondria helping in the treatment of kidney, immune, and liver diseases. Mitotherapeutix's drug candidates MT-001 to MT004 are in the early stage of the preclinical study. The company is targeting diseases like Unilateral Ureter Obstruction, acute liver failure, CD8 T-cells, and its role in treating diseases like cancer among others. The company is using proprietary technology to target the beta-oxidation pathway in the mitochondria.
MITOTHERAPEUTIX
Social Links:
Industry:
Biotechnology Health Care Medical Product Research
Founded:
2014-01-01
Address:
Farmington, Connecticut, United States
Country:
United States
Website Url:
http://www.mitotherapeutix.com
Total Employee:
1+
Status:
Active
Contact:
(203) 676-1709
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Apple Mobile Web Clips Icon WordPress WordPress 6.0 WP Super Cache
Similar Organizations
Palisade Therapeutics
Palisade Therapeutics develops therapeutics-based products for the treatment of neurological diseases.
Current Advisors List
Current Employees Featured
Founder
Official Site Inspections
http://www.mitotherapeutix.com Semrush global rank: 5.26 M Semrush visits lastest month: 1.56 K
- Host name: 108-167-164-165.unifiedlayer.com
- IP address: 108.167.164.165
- Location: Houston United States
- Latitude: 29.8284
- Longitude: -95.4696
- Metro Code: 618
- Timezone: America/Chicago
- Postal: 77092
More informations about "Mitotherapeutix"
Mitotherapeutix, LLC
Mitotherapeutix was created to take advantage of advancements in RNA chemistry and its use in developing siRNA based drugs that can target otherwise difficult to address disease targets. …See details»
About – Mitotherapeutix, LLC
Co-founder and Chairman of the Board. Mr. Hennessey was the former Chairman, President and CEO of Genome Therapeutics, previously known as Collaborative Research.See details»
Mitotherapeutix - Crunchbase Company Profile
Mitotherapeutix develops siRNA-based drugs that focus on addressing difficult disease targets. Mitotherapeutix targets and controls the metabolic activity in the mitochondria helping in the treatment of kidney, immune, and liver diseases.See details»
Mitotherapeutix - MitoWorld
Mitotherapeutix was created to take advantage of advancements in RNA chemistry and its use in developing siRNA based drugs that can target otherwise difficult to address disease targets. …See details»
Mitotherapeutix Company Profile 2024: Valuation, …
Developer of molecules-based drugs designed for the treatment of cancer and degenerative liver disorders.See details»
Mitotherapeutix - BIO International Convention | BIO
Jun 7, 2023 · Mitotherapeutix is a preclinical stage pharmaceutical company that is focused on the development of innovative drugs that can be used to treat metabolic diseases. We are …See details»
Mitotherapeutix LLC - BioCT
Mitotherapeutix aims to develop novel therapeutics based on new discoveries in the control of cellular metabolism particularly in key mitochondria regulators. One of the targets that Mitotherapeutix is currently pursuing is MCJ, a key regulator …See details»
Jack Talley - CEO at Mitotherapeutix - The Org
Interim CEO of the Company. He was the CEO of Izun Pharmaceuticals and previously Alissa Pharmaceuticals, a company involved in the development of radio-immunotherapy with novel targeted antibodies for hematology and solid …See details»
Mitotherapeutix's CEO and Executive Team - The Org
Mitotherapeutix's CEO and Executive Team includes Jack Talley and 3 others. Team members. Cynthia Arbeeny. CSO. Jack Talley. CEO. Patrick Shao. CDO. Robert Hemley. Co-Founder & …See details»
Mitotherapeutix - Biotech Careers
Mitotherapeutix was created to take advantage of advancements in RNA chemistry and its use in developing siRNA based drugs that can target otherwise difficult to address disease targets. …See details»
Mitotherapeutix - Contacts, Employees, Board Members, Advisors …
Mitotherapeutix develops siRNA-based drugs that focus on addressing difficult disease targets.See details»
Mitotherapeutix - VentureRadar
"Mitotherapeutix is a US-based pre-clinical stage pharmaceutical company that is developing drugs (siRNA) targeting metabolism to treat disease. Our initial program targets a protein …See details»
Research, Sponsored Programs, and Innovation ... - Mitotherapeutix
Specific guidance and requirements regarding Public Health Service (PHS), USDA, and NSF funded research at Mitotherapeutix are noted in this policy in Section 5.11. This policy does …See details»
Patrick Shao - CDO at Mitotherapeutix - The Org
CDO and Head of R & D. Dr. Shao is a seasoned drug discovery scientist with two decades of experience in large pharma and biotech industry.See details»
Mitotherapeutix Awarded $2.2 Million SBIR Grant from the
Jun 4, 2021 · Mitotherapeutix is a US-based pre-clinical stage pharmaceutical company that is developing drugs (siRNA) targeting metabolism to treat disease. Our initial program targets a …See details»
Mitotherapeutix Awarded $2.2 Million SBIR Grant from the
Jun 4, 2021 · Mitotherapeutix is a US-based pre-clinical stage pharmaceutical company that is developing drugs (siRNA) targeting metabolism to treat disease. Our initial program targets a …See details»
Technology – Mitotherapeutix, LLC
Mitotherapeutix has identified a unique target for its first program. Our first target is DNAJC15, a gene that is responsible for the production of a peptide MCJ (Methylation Controlled J Protein), …See details»
Cynthia Arbeeny - Mitochondria-Related Drug Development
Company: Mitotherapeutix. Job title: Chief Scientific Officer. Seminars: Pioneering Mito-1041: A Novel siRNA Approach to Modulate Mitochondrial Function for Tissue Selectivity & Specificity …See details»
News & Publications – Mitotherapeutix, LLC
Jul 3, 2020 · Mitotherapeutix Awarded $2.2 Million SBIR Grant from the National Institutes of Health for siRNA NASH Candidates. Apr 19, 2021. Research, Sponsored Programs, and …See details»
Pipeline – Mitotherapeutix, LLC
MT-001 has been tested in a variety of NASH models in mice with success. We have demonstrated that MT-001 can also be effective in the treatment of fibrosis, cirrhosis, and …See details»